Inquiry Basket
Loading ......
Filter By Product Search for
IGF1R
IGF1R Full Name
Insulin-like Growth Factor 1 Receptor
IGF1R Introduction
Researchers and drug developers often struggle to understand how growth-factor signaling drives tumor progression and treatment resistance. Insulin-like Growth Factor 1 Receptor (IGF1R) has emerged as a critical molecular target because it sits at the center of multiple signaling networks controlling cell proliferation, metabolism, and survival. IGF1R is a transmembrane receptor tyrosine kinase activated primarily by its ligands IGF-1 and IGF-2. Once activated, it triggers downstream signaling cascades such as the PI3K/AKT and MAPK pathways, which regulate cellular growth, differentiation, and protection from apoptosis. Because these pathways are fundamental to both normal physiology and tumor development, dysregulated IGF1R signaling has become a major focus in biomedical research, particularly for scientists seeking therapeutic strategies against cancers and metabolic disorders.
From a functional perspective, IGF1R acts as a signaling hub that integrates extracellular growth signals with intracellular programs governing cell fate. Activation of the receptor leads to phosphorylation of adaptor proteins such as IRS and Shc, which subsequently stimulate pathways involved in protein synthesis, glucose metabolism, and cell cycle progression. In cancer biology, these signaling cascades are frequently hijacked to promote uncontrolled proliferation and resistance to cell death. Recent studies have further highlighted the importance of IGF1R in tumor microenvironment communication. For example, cancer-associated fibroblasts can secrete IGF2 to activate the IGF1R pathway in tumor cells, triggering downstream transcriptional regulators such as YAP1 and enhancing tumor invasiveness. Additionally, regulatory molecules including long non-coding RNAs have been shown to modulate IGF1R signaling, demonstrating that the receptor operates within a complex regulatory network that extends beyond traditional ligand-receptor interactions.
Accumulating evidence also links IGF1R signaling to the progression and therapeutic response of multiple human diseases. In colorectal cancer, crosstalk between stromal fibroblasts and tumor cells through the IGF2–IGF1R signaling axis can promote metastasis and tumor progression. In breast cancer, suppression of the IGF1R/PI3K/AKT pathway by tumor-suppressive non-coding RNAs has been shown to inhibit cell proliferation and induce apoptosis, highlighting the pathway's importance in cancer metabolism and growth regulation. More recent studies suggest that IGF1R signaling contributes to epithelial–mesenchymal plasticity in cutaneous squamous cell carcinoma by regulating molecules such as integrin αV, thereby facilitating tumor invasion and metastasis. Beyond tumor cell biology, IGF1R is increasingly recognized as an important regulator of the tumor immune microenvironment, influencing immune cell behavior and potentially affecting the response to modern immunotherapies. As a result, targeting IGF1R is now considered a promising strategy not only for inhibiting tumor growth but also for improving the effectiveness of combination cancer therapies.
Alternate Names for IGF1R
CD221;Insulin-like Growth Factor I Receptor;IGF-I Receptor;IGF-1R;IGF-I-R;Tyrosine-protein kinase IGF1R;p155-IGF1R;Mechano Growth Factor Receptor;MGFR;Insulin-like growth factor IA Receptor;IBP1R;Insulin-like growth factor IB Receptor;Somatomedin-C Receptor;Insulin-like growth factor receptor;IGFR;JTK13;IGF-I receptor;soluble IGF1R variant 1;soluble IGF1R variant 2;
Loading ......
